-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $231

Benzinga·08/11/2026 17:33:51
Listen to the news
Truist Securities analyst Gregory Renza maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $210 to $231.